Skip to main content

Noyes Timothy P's Form 4 filing

Jade Biosciences, Inc. (JBIO) · filed Jan 5, 2023

Accession no.
0001415889-23-000551
Filed
Jan 5, 2023
Trade date
Jan 3, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $406.1K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Noyes Timothy PCIK 0001185035Director, Officer (CHIEF EXECUTIVE OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 3, 2023Common StockMOption exerciseAcquired+15,000$2.14+$32,10015,000Direct
Jan 3, 2023Common StockSSaleDisposed−11,927$26.80F2−$319,643.63,073Direct
Jan 3, 2023Common StockSSaleDisposed−2,267$27.90F3−$63,249.3806Direct
Jan 3, 2023Common StockSSaleDisposed−791$28.78F4−$22,764.9815Direct
Jan 3, 2023Common StockSSaleDisposed−15$29.82−$447.30Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 3, 2023Common StockMOption exerciseDisposed−15,000$0.00$0463,381Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.26 to $27.17, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.32 to $28.29, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.56 to $29.40, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)